Illinois And Irving

ABBOTT PARK, Illinois and IRVING, Texas, December 12, 2011 - - Agreement Calls for 50/50 Global Profit Share for Multiple New Molecules - Companies Plan to Explore Broad Therapeutic Potential of AIM Class Abbott (NYSE: ABT) and Reata Pharmaceuticals today announced that they have entered into a worldwide collaboration to jointly develop and commercialize Reata's portfolio of second-generation oral antioxidant inflammation modulators (AIMs).